Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cns Pharmaceuticals Inc (NQ: CNSP )

0.1112 +0.0012 (+1.09%)
Streaming Delayed Price Updated: 3:12 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cns Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Berubicin’s Potential in Glioblastoma Treatment During KOL Connect Event
Via Investor Brand Network
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Granted Nasdaq Extension for Compliance
Via Investor Brand Network
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Via ACCESSWIRE
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG
Via AB Newswire
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
Via ACCESSWIRE
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
Via ACCESSWIRE
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum
Via ACCESSWIRE
CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Via ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures $3 Million in Registered Direct Offering
Via Investor Brand Network
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Management, Dr. Samuel Goldlust Participate in Virtual Investor KOL Connect Segment
Via Investor Brand Network
Jimmy Carter Survival Thanks to Novel Cancer Immunotherapy Treatment
Via Investor Brand Network
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment
Via ACCESSWIRE
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum
Via Investor Brand Network
WHO Review Says No Link Between Mobile Phones, Brain-Cancer Development
Via Investor Brand Network
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Slated to Present at H.C. Wainwright 26th Annual Global Investment Conference
Via Investor Brand Network
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Via ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Latest BioMedWire Podcast Episode
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Upcoming Virtual Investor CEO Connect Segment
Via Investor Brand Network
Scientists Find Way to Boost Natural Killer Cells Targeting Pediatric Brain Cancer
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Publishes Q2 2024 Results
Via Investor Brand Network
Exposures Product Safety
Study Uncovers How Brain Tumors Evolve During Treatment
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Inks Exclusive License in ‘Transformational’ Step to Treating GBM
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
Via ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CMO to Present Poster at Upcoming SNO/ASCO CNS Cancer Conference
Via Investor Brand Network
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.